11-10-05

NOV 0 9 2005 W

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

DENNIS P. CURRAN et al.

Serial No. 10/655,916

DICTYOSTATIN-1, INTERMEDIATES
Filed: September 5, 2003

THEREFOR AND METHODS OF

SYNTHESIS
Art Unit: 1625

Examiner: BA K TRINH

ANALOGS OF DISCODERMOLIDE AND
DICTYOSTATIN-1, INTERMEDIATES
THEREFOR AND METHODS OF

SYNTHESIS
THEREOF

Pittsburgh, Pennsylvania 15219 November 9, 2005

Mail Stop Amendment Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Atty Dock No.: 02-028

Sir:

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this correspondence and any document referred to as enclosed herewith are being deposited with the United States Postal Service in an envelope as United States Express Mail addressed to Mail Stop Amendment, Commissioner for Patents. P. O. Box 1450, Alexandria, VA 22313-1450

EL903357119US Mailing Lab

Henry E. Bartony, Jr., Registration No 34, 772

November 9, 2005

EXPRESS MAIL LABEL NO. EL903357119US

INFORMATION DISCLOSURE STATEMENT

In compliance with Applicant's duty of disclosure under 37 C.F.R. § 1.56, Applicants submit the attached forms PTO/SB/08A and PTO/SB/08B listing publications for consideration by the Examiner. Kindly, make these publications of record in the file of the application.

11/14/2005 WABDELR1 00000088 021065 10655916 01 FC:1806 180.00 DA

STATEMENT OF RELEVANCY

The relevance of the publications listed on attached forms PTO/SB/08A and PTO/SB/08B is apparent from their disclosure.

The Examiner is respectively requested to initial a copy of the attached forms PTO/SB/08A and PTO/SB/08B to show consideration of the publications, and to return the initialed forms to the undersigned Attorney for Applicants.

Applicants note that although the cited references may be relevant to the examination of the above-referenced application, the filing of this Statement is not an admission that the information cited in the statement is, or is considered to be, prior art or material to patentability as defined in § 1.56(b).

Applicants believe that a fee of \$180.00 is required in connection with this Information Disclosure Statement. The United States Patent and Trademark Office is hereby authorized to charge such a fee to Deposit Account No. 02-1065. The United States Patent and Trademark Office is also hereby authorized to refund any overpayment or charge any deficiency in such fee to Deposit Account No. 02-1065. A duplicate copy of this Information Disclosure Statement is transmitted herewith.

Respectfully submitted,

DENNIS P. CURRAN et al.

Henry E. Bartony, Jr., Esq.

Reg. No. 34,772

Bartony & Hare, LLP

Law & Finance Building

Suite 1801

429 Fourth Avenue

Pittsburgh, Pennsylvania 15219

412-338-8632 (telephone)

412-338-6611 (fax)

Attorney for Applicants

NOV 0 9 2005 E

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
DENNIS P. CURRAN et al.)
Serial No. 10/655,916) ANALOGS OF DISCODERMOLIDE AND
Filed: September 5, 2003	DICTYOSTATIN-1, INTERMEDIATES THEREFOR AND METHODS OF
Art Unit: 1625) SYNTHESIS) THEREOF
Examiner: BA K TRINH)
Atty Dock No.: 02-028)
	Pittsburgh, Pennsylvania 15219 November 9, 2005

Sir:

CERTIFICATION OF EXPRESS MAILING UNDER 37 CFR 1.10

I hereby certify that the attached INFORMATION DISCLOSURE STATEMENT and any documents referred to as enclosed therewith are being deposited with the United States Postal Service on this date NOVEMBER 9, 2005, in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EL903357119US addressed to the: Mail Stop Amendment, Commissioner for Patents. P. O. Box 1450, Alexandria, VA 22313-1450

Henry E. Bartony, Jr.
PERSON MAILING PAPER
SIGNATURE OF PERSON MAILING PAPER
November 9, 2005

DATE -

EXPRESS MAIL LABEL No.: EL903357119US

PTO/SB/08A (07-05) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

der the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of 4

Complete if Known		
Application Number	10/655,916	
Filing Date	SEPTEMBER 5, 2003	
First Named Inventor	DENNIS P. CURRAN	
Art Unit	1625	
Examiner Name	BA K TRINH	-
Attorney Docket Number	02-028	

			U. S. PATEN	DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	^{US-} 5,430,053	07-04-1995	PETTIT	
	 	US-			
		US-			
· · · · · · · · · · · · · · · · · · ·		US-			
		US-			
	 	US-			
		US-			
*		US-			
		US-		i	

		FORE	IGN PATENT DOCL	JMENTS		
Examiner Initials*		Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	Γ	
		Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T⁵
	B1	WO 01/62239	08-30-2001	WRIGHT		
	B2	EP 0 680 958	11-08-1995	UNIV. ARIZONA		
	В3	WO 2004/022552 **	09-05-2003	UNIV. OF PITTSBURGH	" SEARCH REPORT, EXAMINATION REPORT OF THE PCT	
		"INTERNATIONAL APPLICATION CORRESPONDING TO PRESENT PATENT APPLICATION			" WRITTEN OPINION	
	B4	WO 02/12220	02-14-2002	NOVARTIS		
	B5	WO 02/057251	07-25-2002	NOVARTIS		

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

4

of

Sheet

2

PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

Substitute for form 1449/PTO		Complete if Known
	Application Number	10/655,916
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date	SEPTEMBER 5, 2003
	First Named Inventor	DENNIS P. CURRAN
(Use as many sheets as necessary)	Art Unit	1625
	Examiner Name	PA K TDINIH

Attorney Docket Number

02-028

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	NERENBERG, J. B. et.al. Total synthesis of the immunosuppressive agent (-)- discodermolide. J. Am. Chem. Soc. 1993, 115, 12621-12622	
	C2	SMITH, A. B. et.al.;Total Synthesis of (-)- Discodermolide. J. Am. Chem. Soc. 1995, 117, 12011-12012	
	СЗ	MARSHALL, J. A. et.al.; Total synthesis of (+)-discodermolide. J. Org. Chem. 1998, 63, 7885-7892	
	C4	PATERSON, I.et.al; Total synthesis of the antimicrotubule agent (+)-discodermolide using boron mediated aldol reactions of chiral ketones. Angew. Chem., Int. Ed. Eng. 2000, 39, 377-380	
	C5	PATERSON, I.et.al.; Synthesis of (+)-discodermolide and analogues by control of asymmetric induction in aldol reactions of gamma-chiral (Z)-enals. Tetrahedron Lett. 2000, 41, 6935-6939	
	C6	ROUSH, W. R.et.al.; Asymmetric synthesis using tartrate modified allyl boronates. 2. Single and double asymmetric reactions with alkoxy-substituted aldehydes, J. Org. Chem. 1990, 55, 4117-4126	
	C7	PATERSON, I.et.al.; A practical synthesis of (+)-discodermolide and analogues: Fragment union by complex aldol reactions. J. Am. Chem. Soc. 2001, 123, 9535-9544	
	C8	MARTELLO, L. A. et al. The relationship between taxol and (+)-discodermolide: synthetic analogs and modeling studies. Chemistry Biol. 2001, 8, 843-855	
	C9	HARRIED, S. et.al. Total Synthesis of (-)-Discodermolide: An Application of a Chelation-Controlled Alkylation Reaction. J. Org. Chem. 1997, 62, 6098-6099	
	C10	EVANS, D. A.et.al Diastereoselective magnesium halide-catalyzed anti-aldol reactions of chiral N-acyloxazolidinones. J. Am. Chem. Soc. 2002, 124, 392-393	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

	1 pprotou 10. 400 4000
	U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERC
Under the Paperwork Reduction Act of 1995, no persons as	re required to respond to a collection of information unless it contains a valid OMB control number
	The second of th

Substitute for form 1449/PTO		Complete if Known
	Application Number	10/655,916
INFORMATION DISCLOSU	RE Filing Date	SEPTEMBER 5, 2003
STATEMENT BY APPLICA	First Named Inventor	DENNIS P. CURRAN
(Use as many sheets as necessary)	Art Unit	1625
(**************************************	Examiner Name	BA K TRINH
Sheet 3 of 4	Attorney Docket Number	02-028

	Lau	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C11	PETTIT, G. R. et. al; Isolation and structure of the cancer cell growth inhibitor dictyostatin 1. J. Chem. Soc., Chem. Commun. 1994, 1111-1112	
	C12	CAS ONLINE, STN, Columbus, Ohio, USA, 135: 371269, RN 374568-47-5	
	C13	DAY, B. W., et.al;. Convenient syntheses of (2R,3S,4R)-3-(tert-butyldimethylsilanyloxy)-2,4-dimethyl-5-oxopentanoic acid methoxymethyl-amide from methacrolein. Preparation of C1-C7 and C17-C24 fragments of (+)-discodermolide. Tetrahedron Asymmetry 2002, 13, 1161-1165.	
	C14	CLARK, D. L. et. al.; Studies on the alkylation of chiral enolates: application toward the total synthesis of discodermolide. J. Org. Chem. 1993, 58 5878-5879	
	C15	SMITH, A. B et al. Evolution of a gram-scale synthesis of (+)-discodermolide. J. Am. Chem. Soc. 2000, 122, 8654-8664	
	C16	HEATHCOCK, C. H.et.al.;. Acyclic stereoselection-13; Aryl esters: reagents for threo-aldolization. Tetrahedron 1981, 37, 4087-4095.	
	C17	PATERSON, I.et.al.; A. Studies towards the total synthesis of the marine-derived immunosuppresant discodermolide: stereoselective synthesis of a C9-C24 subunit. Synlett. 1995, 498-500.	
	C18	KOCOVSKY, P. Carbamates: a method of synthesis and some synthetic applications. Tetrahedron Lett. 1986, 27 5521-5524	
	C19	FUJIWARA et. al. Synthesis of the Tetrahydropyran Part of a Marine Toxin Polycavernoside-A. Chemistry Letters. 1994, pages 2147-2150.	
	C20	CAS ONLINE, STN, Columbus, Ohio, USA, 124: 86679, RN 172269-30-6P	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05)

Approved for use through 07/31/2006, OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** 10/655,916 INFORMATION DISCLOSURE Filing Date SEPTEMBER 5, 2003 STATEMENT BY APPLICANT **First Named Inventor DENNIS P. CURRAN** Art Unit 1625 (Use as many sheets as necessary) **Examiner Name BAKTRINH** Attorney Docket Number Sheet 4 02-028 of

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²			
	C21	CAS ONLINE, STN, Columbus, Ohio, USA, 66: 94583, RN 16078-24-3P				
		·				

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.